Recurrent Lymphoma Withdrawn Phase 1 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0073930 (Recurrent Lymphoma)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04500548Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyTreatment